Literature DB >> 25048723

Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.

Peter H Wiernik1.   

Abstract

Despite some claims to the contrary, I believe substantial progress has been made in the last half century toward cure of acute myeloid leukemia in children and adults. The tried and true mechanism for this progress has been clinical trial and error. This method has been supplemented with an ever-increasing amount of work at the clinical laboratory interface that is beginning to allow us to develop specific therapy for afflicted individuals. This review details where we stand today and how we got here.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25048723     DOI： 10.1007/s12032-014-0136-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  156 in total

1.  Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

Authors:  Robert E Gallagher; Beow Y Yeap; Wanli Bi; Kenneth J Livak; Nike Beaubier; Sreenivas Rao; Clara D Bloomfield; Frederick R Appelbaum; Martin S Tallman; James L Slack; Cheryl L Willman
Journal:  Blood       Date:  2002-12-05       Impact factor: 22.113

2.  Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

Authors:  Sergio Amadori; Stefan Suciu; Roberto Stasi; Helmut R Salih; Dominik Selleslag; Petra Muus; Paolo De Fabritiis; Adriano Venditti; Anthony D Ho; Michael Lübbert; Xavier Thomas; Roberto Latagliata; Constantijn J M Halkes; Franca Falzetti; Domenico Magro; José E Guimaraes; Zwi Berneman; Giorgina Specchia; Matthias Karrasch; Paola Fazi; Marco Vignetti; Roel Willemze; Theo de Witte; Jean-Pierre Marie
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

3.  Marrow transplantation for acute nonlymphoblastic leukemia in first remission.

Authors:  E D Thomas; C D Buckner; R A Clift; A Fefer; F L Johnson; P E Neiman; G E Sale; J E Sanders; J W Singer; H Shulman; R Storb; P L Weiden
Journal:  N Engl J Med       Date:  1979-09-13       Impact factor: 91.245

4.  Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

Authors:  Hiroto Inaba; Jeffrey E Rubnitz; Elaine Coustan-Smith; Lie Li; Brian D Furmanski; Gerard P Mascara; Kenneth M Heym; Robbin Christensen; Mihaela Onciu; Sheila A Shurtleff; Stanley B Pounds; Ching-Hon Pui; Raul C Ribeiro; Dario Campana; Sharyn D Baker
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

5.  Frozen autologous platelet transfusion for patients with leukemia.

Authors:  C A Schiffer; J Aisner; P H Wiernik
Journal:  N Engl J Med       Date:  1978-07-06       Impact factor: 91.245

6.  Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

Authors:  Ursula Creutzig; Martin Zimmermann; Jean-Pierre Bourquin; Michael N Dworzak; Gudrun Fleischhack; Norbert Graf; Thomas Klingebiel; Bernhard Kremens; Thomas Lehrnbecher; Christine von Neuhoff; Jörg Ritter; Annette Sander; André Schrauder; Arend von Stackelberg; Jan Starý; Dirk Reinhardt
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

7.  Cardiac monitoring of patients receiving arsenic trioxide therapy.

Authors:  Dilip Unnikrishnan; Janice P Dutcher; Susan Garl; Nikita Varshneya; Richard Lucariello; Peter H Wiernik
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

Review 8.  Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.

Authors:  Oliver Teuffel; Kurt Leibundgut; Thomas Lehrnbecher; Todd A Alonzo; Joseph Beyene; Lillian Sung
Journal:  Br J Haematol       Date:  2013-02-08       Impact factor: 6.998

9.  Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

Authors:  Hagop M Kantarjian; Varsha Gandhi; Peter Kozuch; Stefan Faderl; Francis Giles; Jorge Cortes; Susan O'Brien; Nuhad Ibrahim; Fadlo Khuri; Min Du; Mary Beth Rios; Sima Jeha; Peter McLaughlin; William Plunkett; Michael Keating
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

10.  Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.

Authors:  Bob Löwenberg; Joachim Beck; Carlos Graux; Wim van Putten; Harry C Schouten; Leo F Verdonck; Augustin Ferrant; Pieter Sonneveld; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Dimitri Breems; Hilde de Muijnck; Ron Schaafsma; Gregor Verhoef; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gert J Ossenkoppele; Johan Maertens
Journal:  Blood       Date:  2010-01-26       Impact factor: 22.113
View more
  2 in total

1.  Isoquinoline thiosemicarbazone displays potent anticancer activity with in vivo efficacy against aggressive leukemias.

Authors:  Daniel L Sun; Soumya Poddar; Roy D Pan; Ethan W Rosser; Evan R Abt; Juno Van Valkenburgh; Thuc M Le; Vincent Lok; Selena P Hernandez; Janet Song; Joanna Li; Aneta Turlik; Xiaohong Chen; Chi-An Cheng; Wei Chen; Christine E Mona; Andreea D Stuparu; Laurent Vergnes; Karen Reue; Robert Damoiseaux; Jeffrey I Zink; Johannes Czernin; Timothy R Donahue; Kendall N Houk; Michael E Jung; Caius G Radu
Journal:  RSC Med Chem       Date:  2020-02-24

2.  Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML.

Authors:  Ju Huang; Yuanfeng Liu; Bryan C Au; Dwayne L Barber; Andrea Arruda; Axel Schambach; Michael Rothe; Mark D Minden; Christopher J Paige; Jeffrey A Medin
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-07       Impact factor: 6.698
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.